Teprenone and folic acid supplement long-term regresses intestinal metaplasia after H.pylori eradication with endoscopic target surveillance

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPN-16009228

Enrollment

Unknown

Registered

2016-09-20

Start date

2006-02-14

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intestinal metaplasia

Interventions

Prevention Therapy Group:teprenone with folic acid

None Treatment Group:none treatment

Eligibility

Sex/Gender

All

Age

32 Years to 81 Years

Inclusion criteria

Inclusion criteria: Patients who were pathologically diagnosed with intestinal metaplasia were consecutively enrolled between Jun. 2006 and Dec. 2013 at Sir Run Run Shaw Hospital.

Exclusion criteria

Exclusion criteria: (1) initial diagnosed as gastric cancer; (2) with gastric or duodenal ulcers; (3) taking non-steroid anti-inflammatory drug (NSAIDs); (4) history of undergone gastric surgery; (5) refusing repeated endoscopy follow-up. Patients who did not accomplish the prevention trial in one year or withdrew consent for long-term surveillance were also excluded from the study.

Design outcomes

Primary

Measure	Time frame
Intestinal Metaplasia Scores;	—

Countries

China

Contacts

Public ContactLiangjing Wang

Sir Run Run Shaw Hospital

wanglj76@hotmail.com+86 13777848083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026